文献速递生殖医学妇科

BRSK1基因变异可能改变烷化剂化疗相关卵巢功能减退风险

Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究在荷兰DCOG-LATER VEVO队列(n=285)中发现DNA损伤反应通路基因变异与烷化剂化疗后卵巢功能的关系,并在PanCareLIFE(n=465)和St. Jude Lifetime(n=391)队列中验证。荟萃分析显示,携带BRSK1 rs11668344 G等位基因且接受高剂量烷化剂(CED评分≥8000 mg/m2)的儿童癌症女性幸存者,卵巢功能减退的比值增加2.5倍。

要点

  • BRSK1 rs11668344 G等位基因与高剂量烷化剂后卵巢功能减退相关。
  • 高剂量烷化剂定义为环磷酰胺当量剂量评分≥8000 mg/m2。
  • 该发现可能有助于个体化咨询与生育力保存决策。

核心结论

  • 携带BRSK1 rs11668344 G等位基因的儿童癌症女性幸存者,在接受高剂量烷化剂化疗后卵巢功能减退的比值增加2.5倍。

研究设计与样本

  • 多中心回顾性队列研究,发现队列来自荷兰DCOG-LATER VEVO研究(n=285),验证队列为PanCareLIFE(n=465)和St. Jude Lifetime Cohort(n=391)。

主要发现

  • 三个独立队列荟萃分析显示,BRSK1 rs11668344与高剂量烷化剂(CED评分≥8000 mg/m2)对卵巢功能存在显著交互作用(P=3.0×10-4)。
  • rs11668344等位基因频率为0.34。
  • 携带一个G等位基因者相比无该等位基因者,卵巢功能减退(AMH最低三分位)的比值增加2.5倍(基因型AA的OR为2.01,AG的OR为5.00)。

关键数值与推荐

  • 高剂量烷化剂定义为环磷酰胺当量剂量(CED)评分≥8000 mg/m2。
  • 卵巢功能减退以AMH最低三分位定义。
  • BRSK1 rs11668344等位基因频率为0.34。

临床怎么用

  • 对携带BRSK1 rs11668344 G等位基因且需接受高剂量烷化剂化疗的儿童癌症女性患者,可加强卵巢功能监测与生育力保存咨询。

局限性

  • AMH仅为卵巢功能的替代标志物,低AMH水平也可识别辅助生殖技术中的低反应者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n = 465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Müllerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction effect (P = 3.0 × 10-4) between rs11668344 of BRSK1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score ≥8000 mg/m2), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk-contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the PanCareLIFE project that has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. In addition, the DCOG-LATER VEVO study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622) and by the Children Cancer Free Foundation (Project no. 20) and the St Jude Lifetime cohort study by NCI U01 CA195547. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van der Kooi ALF, van Dijk M, Broer L, et al. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. Hum Reprod. 2021. PMID: 33582778. doi:10.1093/humrep/deaa342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。